Beoordeling van blootstelling aan HPHC bij rokers die overstappen op THS/TP18 met verschillende apparaatvarianten
Een gerandomiseerde, gecontroleerde, open-label studie met 6 parallelle armen om de blootstelling aan geselecteerde schadelijke en potentieel schadelijke bestanddelen (HPHC) van sigarettenrook te beoordelen bij volwassen rokers die overstappen naar tabaksverwarmingssystemen (THS/TP18) met verschillende apparaatvarianten in vergelijking met het voortzetten van sigarettenroken
This is a randomized, controlled, open-label, 6 parallel arms study to assess reduced exposure of biomarkers of exposure (BoE) of selected HPHC in smokers switching to TP18 (a prototype heated tobacco device) or THS relative to smokers who continue smoking CIG after 5 days of confinement period, followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This randomized, controlled, open-label study comprises six parallel arms and is designed to evaluate reductions in biomarkers of exposure (BoE) to selected HPHCs in adult smokers switching toTP18 (a prototype heated tobacco device with four variants: THS1, THS2, THS3, THS4) or THS5 relative to smokers who continue smoking CIG after 5 days of confinement period followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.
During the 5-day confinement period, participants will be randomized to use only their assigned product and will operate their assigned devices (THS1, THS2, THS3, THS4, or THS5) with their corresponding sticks or continue smoking CIG ad libitum (6 arms in total).
In the subsequent 2-day PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. Participants randomized to the CIG arm at Baseline will not participate in this period.
During the ambulatory period, participants randomized to one of the TP18 versions at Baseline will be free to choose and use any TP18 variant at any time, ad libitum. Participants randomized at Baseline to TP18 will continue using THS ad libitum. Participants randomized to the CIG arm will only be smoking cigarettes, ad libitum.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Belfast, Verenigd Koninkrijk, BT9 6AD
- Celerion
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participant has signed the ICF and understands the information provided in it.
- Participant is male or female and between 21 and 65 years old (inclusive).
- Participant has been a smoker for at least 2 years prior to the screening visit and is willing to switch to THS and TP18.
- Participant has smoked on average ≥10 commercially available CIGs/day over the last 30 days. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL).
- Participant does not plan to quit smoking within the next three months.
- Participant is available for the entire study period and willing to comply with the study procedures, including product use assignments and periods of abstinence from any nicotine/tobacco-containing products, and willing to adhere to a standardized diet (during confinement period and during overnight stays on Day 30 and Day 60).
Exclusion Criteria:
- As per the Investigator's judgment, the participant cannot participate in the study for any reason other than medical (e.g., psychological, social reason).
- Participant is legally incompetent, or physically or mentally incapable of giving consent (e.g., in emergency situations, under guardianship, prisoners).
- Participant has a health condition which requires medication or any other clinically relevant finding based on available assessments from the Screening period (e.g., safety panel, pulmonary function test, vital signs, physical examination, ECG, and medical history), as determined by the Principal Investigator or designee.
- Participant experienced within 30 days prior to screening/admission a body temperature >37.9°C or an acute illness (e.g., upper respiratory-tract infection, viral infection, etc.).
- According to the Investigator's judgment, the participant has medical conditions that require or will require medical intervention (e.g., initiation of treatment, surgery, hospitalization) during the study period, which may interfere with study participation and/or study results.
- Participant uses medication that aids in smoking cessation.
- Participant experiences difficulty with venipuncture and/or poor venous access.
- Participant has a hemoglobin level < 11.0 g/dL for females and < 12.0 g/dL for males at the Screening visit.
- Participant has a positive nitrite urinary test at screening or on admission day (Day -2)
- Participant has donated blood or received whole blood or blood products within the past 3 months.
- BMI < 18.5 kg/m2 or ≥ 32.0 kg/m2.
- Positive serology test for HIV 1/2, HBV, or HCVa.
- Participant has a positive alcohol breath test and/or has a history of alcohol disorder that could interfere with their participation in the study.
- The participant has a positive urine drug test.
- Participant or one of their family members is a current or former employee of the tobacco industry, manufacturing or distributing e-cigarettes or other nicotine/tobacco-containing products.
- A participant or a family member is an employee of the investigational site or of any other parties involved in the study.
- Participant has participated in another clinical study within 30 days or within a period equivalent to five half-lives of the investigational product from that study, whichever is longer. .
- Participant has been previously screened or enrolled in this study (unless they are alternate subjects).
- Female participant is pregnant (does not have negative pregnancy tests at screening and/or at admission) or is breastfeeding.
- For women of childbearing potential only and males: participant does not agree to use an acceptable method of effective contraception.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: THS1
During the confinement period, participants will use only their assigned product THS 1 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum. |
TP18 prototype variant "1" (THS1) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants. |
|
Ander: THS2
During the confinement period, participants will use only their assigned product THS 2 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum. |
TP18 prototype variant "2" (THS2) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants. |
|
Ander: THS3
During the confinement period, participants will use only their assigned product THS 3 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum. |
TP18 prototype variant "3" (THS3) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants. |
|
Ander: THS4
During the confinement period, participants will use only their assigned product THS 4 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum. |
TP18 prototype variant "4" (THS4) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants. |
|
Ander: THS5
During the confinement period, participants will use only their assigned product THS 5 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they will be continue to use THS5 ad libitum. |
THS 3.0 device (reference) and the corresponding tobacco sticks will be provided by the Sponsor. There are two variants of the sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants may choose either variant or both. |
|
Ander: CIG
During the confinement period, participants will use only their usual brand of commercially available CIG ad libitum. This arm will not participate in the PK period and will move directly to the ambulatory period. During the ambulatory period, participants will smoke only cigarettes, ad libitum. |
Current cigarette smokers will use their usual brand of commercially available CIG. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
3-hydroxypropyl mercapturic acid (3-HPMA) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of 3-HPMA measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
2-cyanoethyl mercapturic acid N-acetyl-S-(2-cyanoethyl)-L-cysteine (2-CyEMA) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of 2-CyEMA measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
Monohydroxybutenyl mercapturic acid (MHBMA) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of MHBMA measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
Total N-nitrosonornicotine (total NNN) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of total NNN measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of total NNAL measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
Carboxyhemoglobin (COHb) in Blood (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Carboxyhemoglobin (COHb) is assayed from whole blood and expressed as percentage of the total hemoglobin saturated with carbon monoxide. |
Measured from Day -1 to Day 5.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
S-phenylmercapturic acid (S-PMA) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of S-PMA measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
2-hydroxyethylmercapturic acid (2-HEMA) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of 2-HEMA measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
3-hydroxy-1-methylpropylmercapturic acid (3-HMPMA) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of 3-HMPMA measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
Total 3-hydroxybenzo(a)pyrene (3-OH-B[a]P) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of 3-OH-B[a]P measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
4-aminobiphenyl (4-ABP) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of 4-ABP measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
|
2-aminonaphtalene (2-NA) in Urine (confinement period)
Tijdsspanne: Measured from Day -1 to Day 5.
|
Concentrations of 2-NA measured in 24-hour urine and expressed as concentration adjusted for creatinine. |
Measured from Day -1 to Day 5.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Plasma nicotine concentrations [C0h] to [C6h] (pharmacokinetic period)
Tijdsspanne: Measured from Day 6 to Day 7.
|
To measure the background-corrected plasma nicotine concentrations (C0h) to (C12h) |
Measured from Day 6 to Day 7.
|
|
Maximum plasma nicotine concentration [Cmax] (pharmacokinetic period)
Tijdsspanne: Measured from Day 6 to Day 7.
|
To measure the background-corrected maximum plasma nicotine concentration [Cmax] |
Measured from Day 6 to Day 7.
|
|
Area under the plasma nicotine concentration-time curve (pharmacokinetic period)
Tijdsspanne: Measured from Day 6 to Day 7.
|
To measure the area under the background-corrected plasma nicotine concentration-time curve (AUC) from the start of product use (T0) to the timepoint of last quantifiable concentration [AUC0-last] and extrapolated to infinity [AUC0-infinity] |
Measured from Day 6 to Day 7.
|
|
Maximum concentration [Tmax] (pharmacokinetic period)
Tijdsspanne: Measured from Day 6 to Day 7.
|
To measure the time to the background-corrected maximum concentration [Tmax] |
Measured from Day 6 to Day 7.
|
|
3-hydroxypropyl mercapturic acid (3-HPMA) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of 3-HPMA measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
2-cyanoethyl mercapturic acid N-acetyl-S-(2- cyanoethyl)-L-cysteine (2-CyEMA) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of 2-CyEMA measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
Monohydroxybutenyl mercapturic acid (MHBMA) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of MHBMA measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
Total N-nitrosonornicotine (total NNN) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of total NNN measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of total NNAL measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
Carboxyhemoglobin (COHb) in Blood (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Carboxyhemoglobin (COHb) is assayed from whole blood and expressed as percentage of the total hemoglobin saturated with carbon monoxide. |
Measured on Day 30 and Day 60.
|
|
S-phenylmercapturic acid (S-PMA) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of S-PMA measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
2-hydroxyethylmercapturic acid (2-HEMA) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of 2-HEMA measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
3-hydroxy-1-methylpropylmercapturic acid (3-HMPMA) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of 3-HMPMA measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
Total 3-hydroxybenzo(a)pyrene (3-OH-B[a]P) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of 3-OH-B[a]P measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
4-aminobiphenyl (4-ABP) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of 4-ABP measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
|
2-aminonaphtalene (2-NA) in Urine (ambulatory period)
Tijdsspanne: Measured on Day 30 and Day 60.
|
Concentrations of 2-NA measured in spot urine and expressed as concentration adjusted for creatinine. |
Measured on Day 30 and Day 60.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Christelle Haziza, PhD, Philip Morris Products S.A.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- P1-REX_PK-22
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .